Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Do not shy away from sexual function discussion, doctors told

Physicians must enquire about erectile dysfunction symptoms in all men who are older than 30 years or have cardiovascular risk factors to ascertain their future cardiac risk, say researchers in the American Heart Journal.

30 Jul 2012

Sleep related diabetes risk needs attention

Strategies aimed at improving sleep quality among individuals without Type 2 diabetes may act as an additional tool in diabetes prevention, report researchers.

30 Jul 2012

Strategies to reduce readmission are lacking in US hospitals

A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.

30 Jul 2012

Osiris second quarter biosurgery product revenue increases 43% from previous quarter

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the second quarter ended June 30, 2012.

30 Jul 2012

Research roundup: Slowdown in medical imaging; Hospitals' efforts mixed on reducing readmissions

Recent research showed a slowdown in the use of medical imaging for people enrolled in Medicare. This article follows up and finds that annual imaging growth slowed down from an average of 14 percent between 2000 and 2005 to 2.6 percent between 2006 and 2009. An analysis of commercial insurance claims shows a similar trend outside of Medicare. Based on

28 Jul 2012

Long-term use of reverse geometry lenses may induce inflammatory response

Continuous long-term overnight use of reverse geometry lenses results in a significantly increased presence of inflammatory mediators compared with wearing 30-night silicone-hydrogel contact lenses or wearing no lenses, show study results.

27 Jul 2012

Mylan receives FDA approval for generic Sporanox ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Itraconazole Capsules, 100 mg.

27 Jul 2012

Rapamycin improves function and extends survival in mice with DCM and rare muscular dystrophies

Rapamycin, an immunosuppressant drug used in a variety of disease indications and under study in aging research labs around the world, improved function and extended survival in mice suffering from a genetic mutation which leads to dilated cardiomyopathy (DCM) and rare muscular dystrophies in humans.

26 Jul 2012

Molecular explanation for increased susceptibility to intestinal inflammation in malnutrition

More than one billion people in poor countries are starving, and malnutrition remains a major problem even in rich countries, making it a leading cause of death in the world. For over a hundred years, doctors have known that a lack of protein in the diet or low levels of amino acids, the building blocks of proteins, can lead to symptoms like diarrhoea, inflamed intestines and other immune system disorders, which weaken the body and can be fatal. However, the molecular mechanism which explains how malnutrition causes such severe symptoms has been largely unexplored.

26 Jul 2012

Jersey Shore continues to provide outstanding cardiac surgery services

The 2012 Cardiac Surgery in New Jersey report, recently released by the New Jersey Department of Health & Senior Services (NJDHSS), shows Jersey Shore University Medical Center continues to provide outstanding cardiac surgery services, building on its exceptional track record in coronary artery bypass graft (CABG) surgery mortality rates.

24 Jul 2012

CHD risk needs separating by glycemic status

People with diabetes not only have a higher incidence of coronary heart disease events compared with people without diabetes, but they differ in the type of risk factors they have for such events, report US researchers.

23 Jul 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

The U.S. Food and Drug Administration today approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy. A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, spongy tissue found inside most bones.

21 Jul 2012

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

Pfizer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU), for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Heart Failure News and Research

Further Reading

Do not shy away from sexual function discussion, doctors told

Sleep related diabetes risk needs attention

Strategies to reduce readmission are lacking in US hospitals

Osiris second quarter biosurgery product revenue increases 43% from previous quarter

Research roundup: Slowdown in medical imaging; Hospitals' efforts mixed on reducing readmissions

Long-term use of reverse geometry lenses may induce inflammatory response

Mylan receives FDA approval for generic Sporanox ANDA

Rapamycin improves function and extends survival in mice with DCM and rare muscular dystrophies

Molecular explanation for increased susceptibility to intestinal inflammation in malnutrition

Jersey Shore continues to provide outstanding cardiac surgery services

CHD risk needs separating by glycemic status

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

A world of consequences due to physical inactivity

Maternal fat indicates birthweight

Telly tubby toddlers at risk for poor health

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News